Skip to main content

22-03-2018 | Biosimilars | Editorial | Article

Biosimilars: The price is not right

Marc D Cohen
A recent medwireNews Hot Topic Review in Medicine Matters rheumatology nicely summarizes the recent emergence of biosimilars in rheumatology [1]. Biosimilars are biologic drugs that are similar to the branded medication already licensed for use, but differ from generic agents because as biologic products they are not exact replicas of the reference product and instead have slight variations. These biologic differences have required new regulatory processes to establish whether or not there are any significant differences in structure, function, efficacy, and safety.

Please log in to get access to this content

Related topics

image credits